Abstract
Therapeutic induction of apoptosis is an important goal of anti-cancer drug design. Here, we review briefly the emerging role of cellular carbonyl stress in melanoma proliferative control, antiapoptotic survival signaling, progression, and metastasis. Cellular carbonyl stress mediated by endogenous reactive carbonyl species (RCS) such as glyoxal, methylglyoxal (MG), and malondialdehyde has been implicated in proliferative signaling and metastasis of human tumor cells. RCS-derived protein-epitopes called advanced glycation endproducts (AGEs) formed from chemical reaction between RCS and tissue proteins are abundant in melanoma tissue, and AGEs are potent ligands of RAGE, a membrane receptor involved in melanoma proliferation and metastasis. In addition to the established role of AGE-RAGE signaling in many human malignancies, increasing experimental evidence supports the hypothesis that RCS, originating from increased tumor cell glycolysis and mitochondrial oxidative stress, are small molecular anti-apoptotic effectors targeting the mitochondrial permeability transition pore (MPTP). We also discuss the emerging role of RCS as novel molecular targets for chemotherapeutic intervention, and provide preliminary experimental evidence that carbonyl scavengers, specific molecular antagonists of RCS, may represent a novel class of anti-melanoma therapeutics.
Keywords: apoptosis, carbonyl scavenger, carbonyl stress, melanoma, mitochondrial permeability transition pore, receptor for advanced glycation endproducts
Current Cancer Therapy Reviews
Title: An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents
Volume: 1 Issue: 3
Author(s): Georg T. Wondrak, Myron K. Jacobson and Elaine L. Jacobson
Affiliation:
Keywords: apoptosis, carbonyl scavenger, carbonyl stress, melanoma, mitochondrial permeability transition pore, receptor for advanced glycation endproducts
Abstract: Therapeutic induction of apoptosis is an important goal of anti-cancer drug design. Here, we review briefly the emerging role of cellular carbonyl stress in melanoma proliferative control, antiapoptotic survival signaling, progression, and metastasis. Cellular carbonyl stress mediated by endogenous reactive carbonyl species (RCS) such as glyoxal, methylglyoxal (MG), and malondialdehyde has been implicated in proliferative signaling and metastasis of human tumor cells. RCS-derived protein-epitopes called advanced glycation endproducts (AGEs) formed from chemical reaction between RCS and tissue proteins are abundant in melanoma tissue, and AGEs are potent ligands of RAGE, a membrane receptor involved in melanoma proliferation and metastasis. In addition to the established role of AGE-RAGE signaling in many human malignancies, increasing experimental evidence supports the hypothesis that RCS, originating from increased tumor cell glycolysis and mitochondrial oxidative stress, are small molecular anti-apoptotic effectors targeting the mitochondrial permeability transition pore (MPTP). We also discuss the emerging role of RCS as novel molecular targets for chemotherapeutic intervention, and provide preliminary experimental evidence that carbonyl scavengers, specific molecular antagonists of RCS, may represent a novel class of anti-melanoma therapeutics.
Export Options
About this article
Cite this article as:
Wondrak T. Georg, Jacobson K. Myron and Jacobson L. Elaine, An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574234
DOI https://dx.doi.org/10.2174/157339405774574234 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Synergistic Antimicrobial Activity of Combinations of Sanguinarine and EDTA with Vancomycin Against Multidrug Resistant Bacteria
Drug Metabolism Letters Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern
Current Drug Safety The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition
Current Medicinal Chemistry Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Treatment of Lung Cancer Using Nanoparticle Drug Delivery Systems
Current Drug Discovery Technologies Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Recent Advances in Curcumin Nanocarriers for the Treatment of Different Types of Cancer with Special Emphasis on In Vitro Cytotoxicity and Cellular Uptake Studies
Nanoscience & Nanotechnology-Asia Black Tea Polyphenols-Mediated In Vivo Cellular Responses During Carcinogenesis
Mini-Reviews in Medicinal Chemistry Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets